Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders
- PMID: 17997341
- DOI: 10.1016/j.diabet.2007.10.004
Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders
Abstract
In the light of recent studies in humans and rodents, AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine protein kinase, has been described as an integrator of regulatory signals monitoring systemic and cellular energy status. AMP-activated protein kinase (AMPK) has been proposed to function as a 'fuel gauge' to monitor cellular energy status in response to nutritional environmental variations. Recently, it has been proposed that AMPK could provide a link in metabolic defects underlying progression to the metabolic syndrome. AMPK is a heterotrimeric enzyme complex consisting of a catalytic subunit alpha and two regulatory subunits beta and gamma. AMPK is activated by rising AMP and falling ATP. AMP activates the system by binding to the gamma subunit that triggers phosphorylation of the catalytic alpha subunit by the upstream kinases LKB1 and CaMKKbeta (calmodulin-dependent protein kinase kinase). AMPK system is a regulator of energy balance that, once activated by low energy status, switches on ATP-producing catabolic pathways (such as fatty acid oxidation and glycolysis), and switches off ATP-consuming anabolic pathways (such as lipogenesis), both by short-term effect on phosphorylation of regulatory proteins and by long-term effect on gene expression. As well as acting at the level of the individual cell, the system also regulates food intake and energy expenditure at the whole body level, in particular by mediating the effects of insulin sensitizing adipokines leptin and adiponectin. AMPK is robustly activated during skeletal muscle contraction and myocardial ischaemia playing a role in glucose transport and fatty acid oxidation. In liver, activation of AMPK results in enhanced fatty acid oxidation as well as decreased glucose production. Moreover, the AMPK system is one of the probable targets for the anti-diabetic drugs biguanides and thiazolidinediones. Thus, the relationship between AMPK activation and beneficial metabolic effects provide the rationale for the development of new therapeutic strategies in metabolic disorders.
Similar articles
-
[Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases].Med Sci (Paris). 2006 Apr;22(4):381-8. doi: 10.1051/medsci/2006224381. Med Sci (Paris). 2006. PMID: 16597407 Review. French.
-
AMP-activated protein kinase in metabolic control and insulin signaling.Circ Res. 2007 Feb 16;100(3):328-41. doi: 10.1161/01.RES.0000256090.42690.05. Circ Res. 2007. PMID: 17307971 Review.
-
The AMP-activated protein kinase: more than an energy sensor.Essays Biochem. 2007;43:121-37. doi: 10.1042/BSE0430121. Essays Biochem. 2007. PMID: 17705797 Review.
-
AMPK: a key regulator of energy balance in the single cell and the whole organism.Int J Obes (Lond). 2008 Sep;32 Suppl 4:S7-12. doi: 10.1038/ijo.2008.116. Int J Obes (Lond). 2008. PMID: 18719601 Review.
-
[AMP-activated protein kinase--the key role in metabolic regulation].Postepy Biochem. 2006;52(3):283-8. Postepy Biochem. 2006. PMID: 17201063 Review. Polish.
Cited by
-
Development of novel adenosine monophosphate-activated protein kinase activators.J Med Chem. 2010 Mar 25;53(6):2552-61. doi: 10.1021/jm901773d. J Med Chem. 2010. Retraction in: J Med Chem. 2018 Jun 14;61(11):5055. doi: 10.1021/acs.jmedchem.8b00707. PMID: 20170185 Free PMC article. Retracted.
-
Exposure to ambient air particulate matter and non-alcoholic fatty liver disease.World J Gastroenterol. 2013 Jul 7;19(25):3951-6. doi: 10.3748/wjg.v19.i25.3951. World J Gastroenterol. 2013. PMID: 23840139 Free PMC article. Review.
-
Metformin: direct inhibition of rat ovarian theca-interstitial cell proliferation.Fertil Steril. 2012 Jul;98(1):207-14. doi: 10.1016/j.fertnstert.2012.04.010. Epub 2012 May 17. Fertil Steril. 2012. PMID: 22608319 Free PMC article.
-
Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease.Metab Brain Dis. 2015 Dec;30(6):1369-77. doi: 10.1007/s11011-015-9706-9. Epub 2015 Jul 9. Metab Brain Dis. 2015. PMID: 26152932
-
Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism.Exp Mol Med. 2011 Apr 30;43(4):205-15. doi: 10.3858/emm.2011.43.4.025. Exp Mol Med. 2011. PMID: 21389766 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials